Galapagos is a pioneering biotech with a pipeline of innovative therapies to address unmet medical needs.

Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Galapagos researchers have gone from target to proof of concept in three lead programs addressing broad disease categories affecting millions worldwide.

Using human primary cells and patient cells, the company discovers which proteins ("targets") play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease, fibrosis and kidney disease. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease itself rather than just treating the symptoms.

Galapagos' aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet need.